FDA inspections underscore issues at major drug compounder; what Congress's PBM reforms would do on drug pricing

Taking stock of the drug industry, from the lab to the medicine chest

July 26, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FDA inspection underscores problem at major U.S. compounder behind hospital drug recalls Over the past decade, several facilities run by Central Admixture Pharmacy Services have drawn attention from the FDA. By Ed Silverman STAT+ | Congress's PBM reforms won't end America's drug pricing woes. Here's what they would do Lawmakers are trying to rein in pharmacy middlemen — but none of their ideas will stop the dynamic that has incentivized higher drug prices. By Rachel Cohrs STAT+ | Democrats already want to expand Medicare drug price negotiation Democrats put out a blueprint for how they hope to expand on a Medicare drug pricing law if they take back control of the House in 2024. By Rachel Cohrs and John Wilkerson Cliff Owen/AP Q&A with CDC Director Mandy Cohen: On communication, trust, and getting things done In a Q&A with STAT, Cohen spoke about rebuilding trust with the agency and what she's learned from previous directors. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser